Top Markets
Coin of the day
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
株式のランク #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
株価
$64.97
最終同期: 2024-05-20
時価総額
$1.97B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Alpine Immune Sciences, Inc. (ALPN)

カテゴリー

Alpine Immune Sciences, Inc.(ALPN)のP/S比率
August 2026 時点のP/S比率 TTM: 75.70
Alpine Immune Sciences, Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 75.70 です。2022 年末時点でのP/S比率は 8.17 でした。
Alpine Immune Sciences, Inc. の P/S 比率の履歴(2012 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
2026 (TTM) 75.70 367.56%
2023 16.19 98.02%
2022 8.17 -45.69%
2021 15.05 -46.46%
2020 28.11 -30.62%
2019 40.52 -43.96%
2018 72.29 72.38%
2017 41.94 256.51%
2016 11.76 -92.02%
2015 147.42 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差
10.17 -86.57%
US
10.13 -86.62%
NL
2.95 -96.10%
AU
11.28 -85.10%
US
- -
CH